BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12243810)

  • 21. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
    Curran WJ; Paulus R; Langer CJ; Komaki R; Lee JS; Hauser S; Movsas B; Wasserman T; Rosenthal SA; Gore E; Machtay M; Sause W; Cox JD
    J Natl Cancer Inst; 2011 Oct; 103(19):1452-60. PubMed ID: 21903745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer.
    Kubota K; Furuse K; Kawahara M; Kodama N; Yamamoto M; Ogawara M; Negoro S; Masuda N; Takada M; Matsui K
    J Clin Oncol; 1994 Aug; 12(8):1547-52. PubMed ID: 8040666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study.
    Bonner JA; McGinnis WL; Stella PJ; Marschke RF; Sloan JA; Shaw EG; Mailliard JA; Creagan ET; Ahuja RK; Johnson PA
    Cancer; 1998 Mar; 82(6):1037-48. PubMed ID: 9506347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer--impact of total treatment time.
    Nyman J; Bergman B; Mercke C
    Acta Oncol; 1998; 37(6):539-45. PubMed ID: 9860311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
    Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
    J Clin Oncol; 1996 Apr; 14(4):1065-70. PubMed ID: 8648358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
    Albain KS; Rusch VW; Crowley JJ; Rice TW; Turrisi AT; Weick JK; Lonchyna VA; Presant CA; McKenna RJ; Gandara DR
    J Clin Oncol; 1995 Aug; 13(8):1880-92. PubMed ID: 7636530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
    Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
    Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
    Bonomi P; Kim K; Fairclough D; Cella D; Kugler J; Rowinsky E; Jiroutek M; Johnson D
    J Clin Oncol; 2000 Feb; 18(3):623-31. PubMed ID: 10653877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma.
    Pignon T; Ruggieri S; Boutin C; Gouvernet J; Irisson M; Juin P; Astoul P
    Cancer; 1999 May; 85(10):2144-50. PubMed ID: 10326692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
    Kim YS; Yoon SM; Choi EK; Yi BY; Kim JH; Ahn SD; Lee SW; Shin SS; Lee JS; Suh C; Kim SW; Kim DS; Kim WS; Park HJ; Park CI
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):76-81. PubMed ID: 15850905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer.
    Crinò L; Latini P; Meacci M; Corgna E; Maranzano E; Darwish S; Minotti V; Santucci A; Tonato M
    Ann Oncol; 1993 Dec; 4(10):847-51. PubMed ID: 8117604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
    J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
    Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15.
    Byhardt RW; Scott CB; Ettinger DS; Curran WJ; Doggett RL; Coughlin C; Scarantino C; Rotman M; Emami B
    Cancer; 1995 May; 75(9):2337-44. PubMed ID: 7712445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
    Albain KS; Swann RS; Rusch VW; Turrisi AT; Shepherd FA; Smith C; Chen Y; Livingston RB; Feins RH; Gandara DR; Fry WA; Darling G; Johnson DH; Green MR; Miller RC; Ley J; Sause WT; Cox JD
    Lancet; 2009 Aug; 374(9687):379-86. PubMed ID: 19632716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.